Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Abionyx Pharma SA
ABNXCurrent price
1.36 EUR
+0.018 EUR (+1.34%)
Last closed
1.35 EUR
Company
abionyx.com
ISIN
FR0012616852
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Paris
Capitalization
48 212 783 EUR
Yield for 12 month
+13.90 %
1Y
3Y
5Y
10Y
15Y
ABNX
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France. Address: 33 43 av. Georges Pompidou Bât. D2, Balma, France, 31130
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.88 EURP/E ratio
–Dividend Yield
–Current Year
+4 680 695 EUR
Last Year
+5 298 063 EUR
Current Quarter
+2 364 558 EUR
Last Quarter
+1 267 016 EUR
Current Year
+1 151 007 EUR
Last Year
+641 578 EUR
Current Quarter
+277 412 EUR
Last Quarter
+317 258 EUR
Key Figures ABNX
1 year
3 years
5 years
10 years
EBITDA
-3 215 960 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-14.12 %
PEG Ratio
–
Return On Equity TTM
-47.16 %
Wall Street Target Price
10.88 EUR
Revenue TTM
4 898 589 EUR
Book Value
0.29 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
10.2 %
Dividend Yield
–
Gross Profit TTM
706 139 EUR
Earnings per share
-0.1 EUR
Diluted Eps TTM
-0.1 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-69.15 %
Dividend Analytics ABNX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABNX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ABNX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
9.1747
Price Sales TTM
9.8422
Enterprise Value EBITDA
-11.0842
Price Book MRQ
4.9413
Financials ABNX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABNX
For 52 weeks
0.92 EUR
1.51 EUR
50 Day MA
1.27 EUR
Shares Short Prior Month
–
200 Day MA
1.2 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart